^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    luxdegalutamide (ARV-766)

    i
    Other names: ARV-766, ARV 766, ARV766
    Associations

    News

    Trials
    Company:
    Arvinas, Novartis
    Drug class:
    Androgen receptor degrader
    Related drugs:
    Associations

    News

    Trials
    5ms
    PROTAC'ing the androgen receptor and other emerging therapeutics in prostate cancer. (PubMed, Expert Rev Anticancer Ther)
    PROTACs, DAARIs, and anitens represent novel and promising AR-targeting therapeutics that may become an important part of prostate cancer treatment in the future. Elucidating mechanisms of resistance, including ability of these agents to target full length AR, may yield further insights into maximal therapeutic efficacy aimed at silencing AR signaling.
    Review • Journal
    |
    AR (Androgen receptor)
    |
    bavdegalutamide (ARV-110) • AC0176 • luxdegalutamide (ARV-766)
    1year
    A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=220, Recruiting, Arvinas Androgen Receptor, Inc. | N=150 --> 220 | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    abiraterone acetate • luxdegalutamide (ARV-766)
    almost2years
    Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer (AACR 2023)
    ARV-766 significantly and dose-dependently inhibits tumor growth in murine LNCaP and VCaP xenograft models, including an enzalutamide-insensitive non-castrated VCaP model. These preclinical data supported the clinical development of ARV-766 for the treatment of men with metastatic CRPC. Selected pre-clinical data along with the chemical structure of ARV-766 will be presented.
    Metastases
    |
    AR (Androgen receptor)
    |
    AR mutation • AR L702H
    |
    Xtandi (enzalutamide) • luxdegalutamide (ARV-766)
    almost2years
    A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC). (ASCO-GU 2023)
    Patients enrolled in the cohort expansion must have received 1–3 prior NHAs (eg, abiraterone or enzalutamide) and ≤2 prior chemotherapy regimens. Enrollment in the phase 2 expansion study is ongoing. Clinical trial information: NCT05067140.
    P2 data • Metastases
    |
    AR (Androgen receptor)
    |
    AR mutation • AR T878A • AR H875Y • AR L702H • AR wild-type
    |
    Xtandi (enzalutamide) • abiraterone acetate • luxdegalutamide (ARV-766)